Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $18.62 Analyst target: $21.64 Upside: 16.22%
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.